title: MTHFR C677T polymorphism is associated with methotrexate-induced myelopathy risk.
authors.affiliation: From the University of Utah (K.J.-S., A.G.S., T.K., D.S., M.G., E.P.Q.); Huntsman Cancer Institute (C.A.P.), Salt Lake City, UT; and University of Vermont Medical Center (N.K.), Burlington.
authors.forename: Kelsey
authors.initials: K
authors.lastname: Juster-Switlyk
authors.affiliation: From the University of Utah (K.J.-S., A.G.S., T.K., D.S., M.G., E.P.Q.); Huntsman Cancer Institute (C.A.P.), Salt Lake City, UT; and University of Vermont Medical Center (N.K.), Burlington.
authors.forename: A Gordon
authors.initials: AG
authors.lastname: Smith
authors.affiliation: From the University of Utah (K.J.-S., A.G.S., T.K., D.S., M.G., E.P.Q.); Huntsman Cancer Institute (C.A.P.), Salt Lake City, UT; and University of Vermont Medical Center (N.K.), Burlington.
authors.forename: Tibor
authors.initials: T
authors.lastname: Kovacsovics
authors.affiliation: From the University of Utah (K.J.-S., A.G.S., T.K., D.S., M.G., E.P.Q.); Huntsman Cancer Institute (C.A.P.), Salt Lake City, UT; and University of Vermont Medical Center (N.K.), Burlington.
authors.forename: Deborah
authors.initials: D
authors.lastname: Stephens
authors.affiliation: From the University of Utah (K.J.-S., A.G.S., T.K., D.S., M.G., E.P.Q.); Huntsman Cancer Institute (C.A.P.), Salt Lake City, UT; and University of Vermont Medical Center (N.K.), Burlington.
authors.forename: Martha
authors.initials: M
authors.lastname: Glenn
authors.affiliation: From the University of Utah (K.J.-S., A.G.S., T.K., D.S., M.G., E.P.Q.); Huntsman Cancer Institute (C.A.P.), Salt Lake City, UT; and University of Vermont Medical Center (N.K.), Burlington.
authors.forename: Cheryl Ann
authors.initials: CA
authors.lastname: Palmer
authors.affiliation: From the University of Utah (K.J.-S., A.G.S., T.K., D.S., M.G., E.P.Q.); Huntsman Cancer Institute (C.A.P.), Salt Lake City, UT; and University of Vermont Medical Center (N.K.), Burlington.
authors.forename: Edward P
authors.initials: EP
authors.lastname: Quigley
authors.affiliation: From the University of Utah (K.J.-S., A.G.S., T.K., D.S., M.G., E.P.Q.); Huntsman Cancer Institute (C.A.P.), Salt Lake City, UT; and University of Vermont Medical Center (N.K.), Burlington. noah.kolb@uvmhealth.org.
authors.forename: Noah
authors.initials: N
authors.lastname: Kolb
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000009:adverse effects*; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics*; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D012307:Risk Factors; D013118:Spinal Cord Diseases / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000235:genetics*
chemical_list: D000964:Antimetabolites, Antineoplastic; C573423:MTHFR protein, human; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D008727:Methotrexate